Evaluating Antibiotic Review Timing, Clinical Characteristics, and Stewardship Interventions to Confront Antimicrobial Resistance: A Retrospective Cohort Study of 640 Patients in Two UK Hospitals Before and During the COVID-19 Pandemic

IntroductionAntimicrobial resistance (AMR) poses a critical global health threat, with projections of 10 million annual deaths by 2050 if left unaddressed. Antimicrobial stewardship (AMS) initiatives, such as the UKHSA Start Smart - Then Focus (SSTF) framework, are vital for optimising antibiotic use. However, the COVID-19 pandemic significantly disrupted AMS practices, leading to increased empirical prescribing and reduced opportunities for timely antibiotic review. MethodsThis retrospective cohort study analysed antibiotic review practices among 640 adult inpatients treated for respiratory tract infections (RTIs) at two secondary care hospitals within an English NHS Trust during 2019 (pre-pandemic) and 2020 (pandemic). Data included demographics, comorbidities, antibiotic classification (WHO AWaRe), review timing (Days 2-3, 4, 7), and AMS interventions aligned with SSTF-CARES outcomes. Statistical analysis was performed using SPSS v22.0. ResultsPatients were predominantly elderly (median age: 78-81), with high prevalence of comorbidities including hypertension (45%) and diabetes (20%). Overall mortality was 15%. Watch antibiotics were most frequently prescribed (46.3%-65.0%), especially during the pandemic, while Reserve antibiotic use remained appropriately low (<2%). Day 2-3 reviews accounted for 48.1%-54.4% of assessments, enabling timely AMS interventions such as de-escalation (up to 27.5%) and cessation (up to 35.6%). Hospital B consistently used more Watch antibiotics and performed more diagnostic imaging compared to Hospital A. Despite pandemic-related operational pressures, early reviews and stewardship activities were sustained. ConclusionTimely antibiotic review, particularly within 72 hours of initiation, supports effective stewardship and improves prescribing outcomes. The COVID-19 pandemic increased use of broad-spectrum agents but did not compromise early review practices. AMS resilience can be strengthened through standardised review protocols, institutional benchmarking, and integration of tools such as WHOs AWaRe classification. Adaptive AMS strategies are essential for maintaining prescribing quality during public health emergencies. Trial RegistrationISRCTN14825813